8-K/A: NRx Pharma Amends 8-K, Details Dura Medical Acquisition

NRx Pharmaceuticals, Inc. filed an amended 8-K to include the financial statements of Dura Medical, LLC, acquired on September 8, 2025, and pro forma combined financials.

Summary

• NRx Pharmaceuticals, Inc. (NRXP) filed an Amendment No. 1 to its Current Report on Form 8-K to provide the financial statements of Dura Medical, LLC and pro forma combined financial statements.
• The acquisition of Dura Medical, a behavioral health and interventional psychiatry practice, by NRx's subsidiary HOPE Therapeutics, Inc., was completed on September 8, 2025.
• The acquisition consideration included $3,262,500 in cash, 6,188 Class A Units of HTX Management Company LLC (rollover equity subject to vesting), and contingent consideration of up to $3,000,000 based on EBITDA targets.
• Dura Medical reported net patient service revenue of $3,261,271 and net income of $504,807 for the year ended December 31, 2024.
• For the six months ended June 30, 2025, Dura Medical reported net patient service revenue of $2,019,113 and net income of $246,503.
• Pro forma combined financials show NRx Pharmaceuticals with a net loss of $(23,202,000) for the six months ended June 30, 2025, and $(25,384,000) for the year ended December 31, 2024, reflecting the combined operations.
• The pro forma balance sheet as of June 30, 2025, shows combined cash and cash equivalents of $335,000, total assets of $5,603,000, and a total deficit of $(35,615,000).
• Acquired intangible assets include trade name and trademarks ($669,000), customer relationships ($605,000), and a non-compete agreement ($527,000), with goodwill of $693,000.

Sentiment

Score: 6

Explanation: The filing provides necessary financial transparency for a completed acquisition of a profitable entity, which is a positive for NRx Pharmaceuticals' strategic expansion. However, NRx's overall pro forma net loss remains significant, and the cash position is reduced post-acquisition, indicating ongoing financial challenges for the parent company. The contingent consideration and rollover equity are structured as future expenses, which will impact future profitability.

Positives

• Dura Medical, the acquired entity, is a profitable behavioral health practice, reporting net income of $504,807 for 2024 and $246,503 for H1 2025.
• Dura Medical has a diversified service offering including advanced therapies like Ketamine, Spravato, TMS, and SGB, catering to both civilian and veteran populations.
• The acquisition expands NRx Pharmaceuticals' clinical care delivery capabilities through its subsidiary HOPE Therapeutics, Inc.
• The acquisition includes identifiable intangible assets such as trade name and trademarks ($669,000), customer relationships ($605,000), and a non-compete agreement ($527,000), indicating established value.

Negatives

• NRx Pharmaceuticals' pro forma combined net loss remains substantial, at $(23,202,000) for H1 2025 and $(25,384,000) for 2024, indicating the acquisition of a profitable entity does not immediately offset NRx's overall losses.
• The pro forma combined cash and cash equivalents are significantly reduced to $335,000 as of June 30, 2025, after accounting for the cash consideration paid for the acquisition.
• The contingent consideration and rollover equity for Dura Medical's member are structured as post-employment compensation, which will be recognized as expense in future periods.

Risks

• Dura Medical's operations are subject to extensive federal and state healthcare regulations, including Medicare/Medicaid rules and HIPAA.
• Changes in reimbursement rates, regulatory requirements, or economic conditions could materially impact Dura Medical's operations and financial condition.
• Dura Medical derives a significant portion of its revenue from a limited number of third-party payors, posing concentration risk.
• Dura Medical maintains cash accounts in financial institutions that may exceed federally insured limits, exposing it to concentration of credit risk.
• Professional liability risks exist, and while malpractice insurance is maintained, ultimate liability may differ from estimates.
• Legal proceedings in the ordinary course of business could arise, though management currently believes no material loss accrual is required.

Future Outlook

The filing primarily provides historical and pro forma financial data related to the completed acquisition of Dura Medical. It notes that contingent consideration of up to $3,000,000 is payable over three years based on the achievement of specified EBITDA performance targets, which implies an expectation of future profitability or growth from Dura Medical.

Management Comments

• Jonathan Javitt, Interim Chief Executive Officer of NRx Pharmaceuticals, Inc., signed the report, indicating formal acknowledgment of the filing's contents.

Industry Context

The acquisition of Dura Medical, a behavioral health and interventional psychiatry practice, by NRx Pharmaceuticals' subsidiary HOPE Therapeutics, Inc., aligns with a broader trend in the healthcare industry towards integrating specialized mental health services, particularly those offering innovative therapies like ketamine and TMS. This move positions NRx to expand its footprint in the growing outpatient mental health sector, which is experiencing increased demand for advanced treatment options for conditions like depression, anxiety, and PTSD, including services for military veterans.

Legal Proceedings

• Dura Medical is party to legal proceedings in the ordinary course of business.
• Management does not believe matters exist that would require a probable and estimable loss accrual as of December 31, 2024, or June 30, 2025.

Related Party Transactions

• Dura Medical leases its Naples clinic from Dura Properties, LLC, an entity owned and controlled by Dura Medical's sole member.
• Rent expense under this related-party lease was $76,680 for the year ended December 31, 2024, and $38,340 for the six months ended June 30, 2025.
• Lease terms are stated to approximate market conditions, with monthly payments and no unusual guarantees or concessions.

Stakeholder Impact

• Shareholders (NRx Pharmaceuticals): Gain transparency regarding the financial performance of the acquired entity and its pro forma impact on NRx's financials. The acquisition of a profitable entity could be seen as a long-term strategic positive, but the immediate pro forma net loss and reduced cash position highlight ongoing challenges.
• Employees (Dura Medical): The sole member's continued employment is incentivized through rollover equity, suggesting stability for key personnel.
• Customers (Dura Medical patients): Continued access to behavioral health and interventional psychiatry services, potentially benefiting from integration with NRx's broader healthcare initiatives.
• Creditors (NRx Pharmaceuticals): The pro forma financials provide updated information on the combined entity's financial health, including liabilities and cash position.

Next Steps

• NRx Pharmaceuticals will consolidate Dura Medical, LLC into its financial statements and those of HOPE Therapeutics, Inc. beginning on the closing date of September 8, 2025.
• The 6,188 Class A Units of HTX Management Company LLC issued as rollover equity will vest in equal annual installments over a three-year period, subject to continued employment of Dura Medical's member.
• Contingent consideration of up to $3,000,000 will be paid over three years based on the achievement of specified EBITDA performance targets by Dura Medical.
• NRx Pharmaceuticals will complete the final purchase price allocation for the acquisition within one year of the acquisition date.
• The Company is evaluating the impact of ASU 2024-03 on its financial statements, effective for fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

The filing provides necessary financial details for a completed acquisition, which is a positive for transparency and strategic expansion into a growing healthcare segment. Dura Medical is a profitable entity, which could contribute positively to NRx's long-term revenue. However, NRx Pharmaceuticals continues to report significant pro forma net losses, and the cash position is notably reduced post-acquisition. While the acquisition adds a valuable asset, it does not immediately resolve NRx's underlying financial challenges, warranting a 'hold' as investors await further operational updates and evidence of synergistic benefits.

Keywords

NRx Pharmaceuticals, Dura Medical, Acquisition, 8-K/A, Financial Statements, Pro Forma, Behavioral Health, Interventional Psychiatry, HOPE Therapeutics, SEC Filing, Healthcare, Mental Health, Ketamine, TMS, SGB, Corporate Governance, Risk Management